Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

VitaNova Life Sciences (YJGJ) Debt to Equity (2017 - 2025)

VitaNova Life Sciences (YJGJ) has disclosed Debt to Equity for 9 consecutive years, with $0.09 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Debt to Equity rose 84.77% year-over-year to $0.09, compared with a TTM value of $0.09 through Jan 2025, up 84.77%, and an annual FY2024 reading of $0.0, up 101.04% over the prior year.
  • Debt to Equity was $0.09 for Q1 2025 at VitaNova Life Sciences, down from $0.12 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.12 in Q4 2024 and bottomed at -$1.48 in Q1 2022.
  • Average Debt to Equity over 5 years is -$0.37, with a median of -$0.29 recorded in 2023.
  • The sharpest move saw Debt to Equity plummeted 50.94% in 2022, then surged 170.25% in 2024.
  • Year by year, Debt to Equity stood at -$0.71 in 2021, then skyrocketed by 43.48% to -$0.4 in 2022, then surged by 55.98% to -$0.18 in 2023, then surged by 170.25% to $0.12 in 2024, then fell by 25.6% to $0.09 in 2025.
  • Business Quant data shows Debt to Equity for YJGJ at $0.09 in Q1 2025, $0.12 in Q4 2024, and $0.06 in Q3 2024.